NCT03141021 Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
| NCT ID | NCT03141021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Malignant Peripheral Nerve Sheath Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,050 participants |
| Start Date | 2017-04-28 |
| Primary Completion | 2053-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,050 participants in total. It began in 2017-04-28 with a primary completion date of 2053-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.
Eligibility Criteria
Inclusion Criteria and Exclusion Criteria: -Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s/he consents to participate (or consent form his/her parent or legal guardian or legally authorized representative is obtained).
Contact & Investigator
Angela Hirbe, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT03141021 clinical trial?
This trial is open to participants of all sexes, studying Malignant Peripheral Nerve Sheath Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03141021 currently recruiting?
Yes, NCT03141021 is actively recruiting participants. Contact the research team at hirbea@wustl.edu for enrollment information.
Where is the NCT03141021 trial being conducted?
This trial is being conducted at Tampa, United States, Baltimore, United States, Bethesda, United States, Boston, United States and 9 additional locations.
Who is sponsoring the NCT03141021 clinical trial?
NCT03141021 is sponsored by Washington University School of Medicine. The principal investigator is Angela Hirbe, M.D., Ph.D. at Washington University School of Medicine. The trial plans to enroll 1,050 participants.